Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression.
Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, Bocharov EV, Bocharova OA, Polyschuk VV, Sherstnev VV, Morozova-Roche LA.
Gruden MA, et al. Among authors: sherstnev vv.
J Neuroimmunol. 2011 Apr;233(1-2):221-7. doi: 10.1016/j.jneuroim.2010.12.001. Epub 2011 Jan 15.
J Neuroimmunol. 2011.
PMID: 21239064